Experimental Ebola vaccines elicit year-long immune response

(NIH/National Institute of Allergy and Infectious Diseases) Results from a large randomized, placebo-controlled clinical trial in Liberia show that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses by one month after initial vaccination that last for at least one year. The findings, published in NEJM, are based on a study of 1,500 adults that began during the West Africa Ebola outbreak. The trial is being conducted by a US-Liberia clinical research collaboration known as PREVAIL.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news